OncoMatch/Clinical Trials/NCT06780137
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Is NCT06780137 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Gocatamig and Ifinatamab Deruxtecan (I-DXd) for small cell lung cancer.
Treatment: Gocatamig · Ifinatamab Deruxtecan (I-DXd) · Durvalumab — Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn: * If gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated * If people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Prior therapy
Must have received: systemic therapy including platinum-based chemotherapy
following at least 1 prior line of systemic therapy that included platinum-based chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado Anschutz Medical Campus ( Site 1110) · Aurora, Colorado
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111) · Miami, Florida
- University of Chicago ( Site 1108) · Chicago, Illinois
- Dana Farber Cancer Institute ( Site 1105) · Boston, Massachusetts
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103) · Hackensack, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06780137 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy including platinum-based chemotherapy.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages